Previous Close | 1.2900 |
Open | 1.2700 |
Bid | 0.9800 x 1400 |
Ask | 1.0300 x 1200 |
Day's Range | 1.2700 - 1.3800 |
52 Week Range | 0.4700 - 7.4600 |
Volume | |
Avg. Volume | 238,518 |
Market Cap | 40.269M |
Beta (5Y Monthly) | 0.82 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5300 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for DRRX
DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET® Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada. Charles River is a highly respected, global provider of drug discovery and non-clinical development solutions.
Pacira (PCRX) delivered earnings and revenue surprises of 0% and 0.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually, February 13-14, 2024.